Xavier Dezitter

Xavier Dezitter

Auto-generated profile, based on publicly available information

Xavier Dezitter

Univ. Lille, Inserm, CHU Lille, U1286─INFINITE─Institute for Translational Research in Inflammation

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RNRaja Nhili
Raja Nhili
PPPaul Peixoto
Paul Peixoto
SDSabine Depauw
Sabine Depauw
SFSébastien Flajollet
Sébastien Flajollet
XDXavier Dezitter
Xavier Dezitter
MDMarie-Helene David-Cordonnier
Marie-Helene David-Cordonnier
Direct modulation of gene expression by targeting oncogenic transcription factors is a new area of research for cancer treatment. ERG, an ETS-family transcription factor, is commonly over-expressed or translocated in leukaemia and prostate carcinoma. In this work, we selected the di-(thiophene-phenyl-amidine) compound DB1255 as an ERG/DNA binding inhibitor using a screening test of synthetic inhibitors of the ERG/DNA interaction followed by electrophoretic mobility shift assays (EMSA) validation. Spectrometry, footprint and biosensor-surface plasmon resonance analyses of the DB1255/DNA interaction evidenced sequence selectivity and groove binding as dimer. Additional EMSA evidenced the precise DNA-binding sequence required for optimal DB1255/DNA binding and thus for an efficient ERG/DNA complex inhibition. We further highlighted the structure activity relationships from comparison with derivatives. In cellulo luciferase assay confirmed this modulation both with the constructed optimal sequences and the Osteopontin promoter known to be regulated by ERG and which ERG-binding site was protected from DNaseI digestion on binding of DB1255. These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site.

1 August 2011 in Oncogene
Verified
Journal Article
Open access
SJS Joha
S Joha
ANA-L Nugues
A-L Nugues
DHD Hétuin
D Hétuin
CBC Berthon
C Berthon
XDX Dezitter
X Dezitter
TIT Idziorek
T Idziorek
The malignant phenotype of chronic myeloid leukemia (CML) is due to the abnormal tyrosine kinase activity of the BCR-ABL oncoprotein, which signals several downstream cell survival pathways, including phosphoinositide 3-kinase/AKT, signal transducer and activator of transcription 5 and extracellular signal-regulated kinase 1/2. In patients with CML, tyrosine kinase inhibitors (TKIs) are used to suppress the BCR-ABL tyrosine kinase, resulting in impressive response rates. However, resistance can occur, especially in acute-phase CML, through various mechanisms. Here, we show that the glucocorticoid-induced leucine zipper protein (GILZ) modulates imatinib and dasatinib resistance and suppresses tumor growth by inactivating the mammalian target of rapamycin complex-2 (mTORC2)/AKT signaling pathway. In mouse and human models, GILZ binds to mTORC2, but not to mTORC1, inhibiting phosphorylation of AKT (at Ser473) and activating FoxO3a-mediated transcription of the pro-apoptotic protein Bim; these results demonstrate that GILZ is a key inhibitor of the mTORC2 pathway. Furthermore, CD34+ stem cells isolated from relapsing CML patients underwent apoptosis and showed inhibition of mTORC2 after incubation with glucocorticoids and imatinib. Our findings provide new mechanistic insights into the role of mTORC2 in BCR-ABL+ cells and indicate that regulation by GILZ may influence TKI sensitivity.

17 September 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GHGermain Homerin
Germain Homerin
Samir JawharaSamir Jawhara
Samir Jawhara
XDXavier Dezitter
Xavier Dezitter
DBDavy Baudelet
Davy Baudelet
PDPierrick Dufrénoy
Pierrick Dufrénoy
AGAlina Ghinet
Alina Ghinet

4 April 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RBRaphaël Le Biannic
Raphaël Le Biannic
RMRomain Magnez
Romain Magnez
FKFrédérique Klupsch
Frédérique Klupsch
NLNatascha LELEU-CHAVAIN
Natascha LELEU-CHAVAIN
BTBryan Thiroux
Bryan Thiroux
RMRégis Millet
Régis Millet

1 February 2014 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
XDXavier Dezitter
Xavier Dezitter
JFJérôme Fagart
Jérôme Fagart
STSolenne Taront
Solenne Taront
MFMichel Fay
Michel Fay
BMBernadette Masselot
Bernadette Masselot
TIThierry Idziorek
Thierry Idziorek
There is a therapeutic need for glucocorticoid receptor (GR) ligands that distinguish between the transrepression and transactivation activity of the GR, the later thought to be responsible for side effects. These ligands are known as “dissociated glucocorticoids” (dGCs). The first published dGCs, RU24782 (9α-fluoro-11β-hydroxy-16α-methylpregna-21-thiomethyl-1,4-diene-3,20-dione) and RU24858 (9α-fluoro-11β-hydroxy-16α-methylpregna-21-cyanide-1,4-diene-3,20-dione), do not have the 17α-hydroxyl group that characterizes dexamethasone (Dex; 9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione), and they differ from one another by having C21-thiomethyl and C21-cyanide moieties, respectively. Our aim was therefore to establish the structural basis of their activity. Both RU24782 and RU24858 induced a transactivation activity highly dependent on the GR expression level but always lower than dexamethasone. They also display less ability than dexamethasone to trigger steroid receptor coactivator 1 (SRC-1) recruitment and histone H3 acetylation. Docking studies, validated by mutagenesis experiments, revealed that dGCs are not anchored by Gln642, in contrast to Dex, which is hydrogen bonded to this residue via its 17α-hydroxyl group. This contact is essential for SRC-1 recruitment and subsequent dexamethasone-induced GR transactivation, but not transrepression. The ability of dGCs to make contacts with Ile747, for both RU24858 and RU24782 and with Asn564 for RU24858 are not strong enough to maintain GR in a conformation able to efficiently recruit SRC-1, unless SRC-1 is overexpressed. Overall, our findings provide some structural guidelines for the synthesis of potential new dissociated glucocorticoids with a better therapeutic ratio.

1 October 2014 in Journal of Chromatography A
Verified
Journal Article
Closed access
DBDavy Baudelet
Davy Baudelet
NSNadège Schifano-Faux
Nadège Schifano-Faux
AGAlina Ghinet
Alina Ghinet
XDXavier Dezitter
Xavier Dezitter
FBFlorent Barbotin
Florent Barbotin
ELEmmanuelle Lipka
Emmanuelle Lipka